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1,9,10-SUBSTITUTED PHENOTHIAZINE
DERIVATIVES WITH STRAINED RADICAL
CATIONS AND USE THEREOF

overcharge protection has been demonstrated for lowervoltage LiFePO4 cathodes,[ 3 a. 9 J which require shuttles that
oxidize at potentials of 3.8 to 3.9 V vs. Li+m_ However, the
protection of higher-voltage cathodes (i.e. LiCoO 2 ,
LiMnO 2 , and LiNi 113 Mn113 Co 113 O 2 ) require oxidation
potentials of 4.2 V or higher, and no shuttle has provided
extensive protection in cells containing graphitic anodes.
Maximizing both the energy density and the durability of
a LIBs requires charging to a precise voltage: below that
potential, the full capacity of the cell is not utilized; at higher
potentials, a cell enters overcharge, a condition that can
seriously degrade LIBs and lead to hazardous operating
conditions. [3 l
The road to higher oxidation potential shuttles via the
incorporation of strong electron-withdrawing groups on
viable low-voltage shuttles can introduce perils in the framework of LIB s. Electron-withdrawing substituents shift both
the oxidation and reduction potentials to more positive
values, producing compounds that are more susceptible to
decomposition through subsequent reactions after reduction
to the radical anion at the anode_E?a.rnJ Premature failure of
phenothiazine redox shuttles containing chlorine, bromine,
cyano, or nitro groups can be traced back to having reduction potentials >O V vs. Li+/0[ 7 a.10eJ Dimethoxybenzene
derivatives containing strongly electron-withdrawing
groups have short-lived performance in overcharge when
incorporated into lithium-ion cells containing graphite
anodes, [IOa-dJ perhaps as a result of reductive decomposition
at the anode/electrolyte interface. This is supported by
reports of the redox shuttle 1,4-di-tert-butyl-2,5-bis(2,2,2trifluoroethoxy)benzene surviving 2x longer in a cells containing the Li4 Ti 5 O 12 anode when compared to LIBs with
either the highly reducing graphitic or lithium metal
anodes. [IObJ
As such, the incorporation of strongly electron-withdrawing groups is a problematic route for molecules that require
stability at both high and low redox potentials. Thus, a new
approach for designing stable, high-voltage redox shuttles is
needed.

PRIORITY

5

This invention claims priority to U.S. Provisional Application Ser. No. 62/364,060 filed Jul. 19, 2016.
GOVERNMENT INTEREST

10

This invention was made with govermnent support under
grant number 1300653 awarded by the National Science
Foundation. The govermnent has certain rights in the invention.
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TECHNICAL FIELD
The presently-disclosed subject matter generally relates to
substituted phenothiazine derivatives that contain substituents at the 1,10 position or at the 1,9,10 position that raise
oxidation potentials regardless of whether the substituent is
electron-donating or electron withdrawing, without necessarily concomitantly raising reduction potentials.

20

25

INTRODUCTION
The redox potentials of it-conjugated organic molecules
and polymers are important factors that determine, in part,
their performance in organic electronic devices and in
energy collection and storage applications. In these systems,
the general prescriptions to control redox potentials involve
substitution with electron-donating and/or electron-withdrawing groups, making use of the well-known Hammett
constants as predictors of the extent of the change of redox
potentials, [IJ and/or modifying the length of the it-conjugation pathway, e.g. going from ethylene to butadiene to
hexatriene and beyond.
Another route to modify molecular redox potentials
exploits strain-induced disruptions of the it-conjugated
framework) Such chemical modifications typically use socalled bulky substituents to manipulate the dihedral torsions
among the it-conjugated moieties that make up the molecular systems. Prime examples include biphenyl (or more
generally oligo- or polyphenylenes), where substituents
incorporated at the 2, 2', 6, and/or 6' positions increase the
twist angle between the phenyl groups, and oligothiophenes,
where similar tactics are employed with substituents placed
at the 3 and/or 4 positions) Notably, these considerations
have been widely used in the development of it-conjugated
polymers for electronics and solar cell applications.
Strain has also been used to instill curvature into it-conjugated networks to alter optical and/or redox characteristics, for example in fullerenes,[ 4 l cyclized stilbenes,E5l and
twisted acenes ( so-called 'twistacenes '). [6 l In each of these
latter examples, the it-conjugated networks are strained in
both the ground (neutral) and ionized (oxidized or reduced)
electronic states.
Molecular redox shuttles can be used to mitigate excess
current in overcharging batteries by spatially ferrying charge
through a series of electron-transfer reactions, oxidizing to
their radical-cation form at the cathode and reducing to their
neutral form at the anode. For molecules designed to mitigate overcharge in LIBs, chemical substitutions are made to
adjust the oxidation potentials with respect to the reduction
potential of the cathode to ensure that the shuttles become
redox active just after a cell is fully charged. [3 l Extensive
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In some embodiments of the subject matter, the phenothiazine derivatives presently disclosed can be used in
rechargeable batteries to confer overcharge protection in
such batteries. In particular, certain embodiments of the
presently-disclosed subject matter relate to conferring overcharge protection in lithium-ion batteries and/or lithium-air
batteries and/or redox flow batteries.
In some embodiments of the subject matter, the phenothiazine derivatives can be used as photo-redox catalysts,
photoinitiators, redox mediators in electrochemical surface
patterning, and in other applications.
Embodiments of compounds disclosed herein are substantially more planar in their radical-cation states as compared
to their neutral states. Embodiments of compounds disclosed
herein have increased oxidation potentials without requiring
use of electron-withdrawing groups, leading to less-easily
accessed reduction potentials.
In some embodiments, the phenothiazine compound is
provided according to the formula:

US 10,854,911 B2
4

3

In some embodiments of the formula, R 1 and R9 are
(V)
independently selected from the group consisting of H,
alkyl, aryl, perfluoroaryl, perfluoroalkyl, alkylaryl, alkoxyaryl, alkylcarboxyl, aryl carbonyl, haloalkyl, perfluoroalkyl, glycols, haloaryl, a negative electrolyte, and a poly- 5
mer, so long as when R 1 is H, R9 is not H. In some
embodiments, R3 and R7 are independently selected from the
group consisting of H, alkyl, perfluoroalkyl, alkylaryl,
alkoxyaryl, alkylcarboxyl, aryl carbonyl, haloalkyl, perfluo10
roalkyl, glycols, haloaryl, a negative electrolyte, and a
In some embodiments, the compound has the structure of
polymer. The term negative electrolyte is well understood to
formula VI.
those of ordinary skill in the art. In some embodiments, R 10
is selected from the group consisting of methyl, alkyl, aryl,
alkylaryl, alkoxyaryl, alkylcarboxyl, aryl carbonyl, 15
(VI)
haloalkyl, perfluoroalkyl, perfluoroaryl, glycols, haloaryl, an
CH3y
CH3
oligomer, and a polymer.
As will be recognized by those of ordinary skill in the art,
examples of negative electrolytes include, but are not limited to, quinones, pyridines, pyrenes, nictotinamides, qui- 20
noxaline compounds, dipyridyl ketone compounds, and
viologen compounds, among other electrochemically reducible conjugated organic molecules. The term polymer is also
well understood to those of ordinary skill in the art. As will
In some embodiments, the compound has the structure of
be recognized by those of ordinary skill in the art, examples 25 formula VII.
of polymers that can be used in accordance with the presently-disclosed subject matter include, but are not limited to,
oligoglycols and polyethylene glycols, polyacrylates, poly(VII)
carbonates, and other polymers that are soluble in an organic
solvent.
30
In some embodiments, the compound has the structure of
formula II.

AvN+
USN

(II) 35

40

In some embodiments, the compound has the structure of
formula VIII.

In some embodiments, the compound has the structure of
formula III.

(VIII)

45

BRIEF DESCRIPTION OF THE DRAWINGS
In some embodiments, the compound has the structure of
formula IV.

55

(IV)

60

65

In some embodiments, the compound has the structure of
formula V.

The novel features of the invention are set forth with
particularity in the appended claims. A better understanding
of the features and advantages of the present invention will
be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the
principles of the invention are used, and the accompanying
drawings of which:
FIG. 1 depicts the structures of various phenothiazine
derivatives.
FIG. 2 includes representations of the potential energy
surfaces for the oxidation of EPT, 3,7-DMeEPT, and 1,9DMeEPT. The gray arrow with a dotted line depicts the
vertical ionization process from ground-state, neutral spe-

US 10,854,911 B2
5

6

cies. Shaded regions represent relaxation energies in the
radical-cation potential energy surfaces. The change in IP is
given by MP.
FIG. 3 shows cyclic voltammograms of EPT, 3,7DMeEPT, 1,9-DMeEPT, 1,9-DMeiPrPT, and 1,9-DMePhPT
at 1.6mMin0.1 MnBu4 NPF 6 in DCM. Voltammograms are
calibrated to Cp 2 Fe+10 at O V, and recorded at 100 mV/s.
FIG. 4 includes cyclic voltammograms of EPT, 3,7DMeEPT, 1,9-DMeEPT, 1,9-DMeiPrPT, and 1,9-DMePhPT
at 1.6 mM in 0.1 M nBu4 NPF 6 in DCM vs. Cp 2 Fe+io at O V,
recorded at scan rates of 100 mV/s.
FIGS. Sa and Sb are UV-vis absorption spectra of EPT,
3,7-DMeEPT, 1,9-DMeEPT, 1,9-DMeiPrPT, and 1,9DMePhPT in their neutral (a) and radical cation (b) forms at
14 µM and 0.1 mM, respectively, in DCM. Note: No
spectrum is reported for the 1,9-DMePhPT radical cation
due to its irreversible first oxidation event.
FIG. 6 depicts minimized structures and butterfly angles
for the neutral (top) and radical cation (bottom) states of
1,9-DMeiPrPT and 1,9-DMePhPT obtained from DFT calculations at the B3LYP/6-311G(d,p) level of theory.
FIG. 7 includes a thermal ellipsoid plot for the 1,9DMeEPT molecule.
FIG. 8 includes a thermal ellipsoid plot for the 1,9DMeiPrPT molecule.
FIG. 9 includes a thermal ellipsoid plot for one molecule
of 1,9-DMePhPT. This structure contained four chemically
equivalent but crystallographically independent molecules.
FIG. 10 includes a thermal ellipsoid plot for one molecule
of N-ethyl-1,9-dimethyl-3, 7-bis(trifluoromethyl)phenothiazme.
FIG. 11 includes cyclic voltammograms of EPT, 3,7DMeEPT, 1,9-DMeEPT, 1,9-DMeiPrPT, and 1,9-DMePhPT
at 1.6 mM in 0.1 M nBu4 NPF 6 in DCM vs. Cp 2 Fe+io at O V,
containing ferrocene or decamethylferrocene as an internal
reference, recorded at scan rates of 100 mV/s.
FIGS.12a-12e are 1 H and 13 C NMR spectra of the neutral
compounds of (a) Bis(o-tolyl)amine, (b) 1,9-DMePT, (c)
1,9-DMeEPT, (d) 1,9-DMeiPrPT, and (e) 1,9-DMePhPT.

(LIBs). As detailed herein, the present inventors have demonstrated molecular design principles to dictate the relaxation processes of it-conjugated molecules through strain
solely in their ionized state, while imparting minimal change
to the ground-state characteristics, as an effective way to
synthetically control redox potentials.

5

Some embodiments of the presently-disclosed subject
matter include a compound which has the structure of
formula I.
10

(I)

15

20

25
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DESCRIPTION OF EXEMPLARY
EMBODIMENTS
The details of one or more embodiments of the presentlydisclosed subject matter are set forth in this document.
Modifications to embodiments described in this document,
and other embodiments, will be evident to those of ordinary
skill in the art after a study of the information provided in
this document. The information provided in this document,
and particularly the specific details of the described exemplary embodiments, is provided primarily for clearness of
understanding and no unnecessary limitations are to be
understood therefrom. In case of conflict, the specification of
this document, including definitions, will control.
The presently-disclosed subject matter includes rechargeable batteries and compounds for use in such batteries.
Compounds disclosed herein are useful for conferring overcharge protection, for example. Compounds disclosed
herein also include those which are substantially more
planar in their radical-cation states as compared to their
neutral states, and which have increased oxidation potentials
without requiring use of electron-withdrawing groups, leading to less-easily accessed reduction potentials.
The possibility of raising phenothiazine oxidation potentials without incorporating electron-withdrawing groups was
explored by the present inventors in connection with their
work on overcharge protection of lithium-ion batteries

wherein
R 1 and R9 are independently selected from the group
consisting of H, alkyl, aryl, perfluoroaryl, perfluoroalkyl,
alkylaryl, alkoxyaryl, alkylcarboxyl, aryl carbonyl,
haloalkyl, perfluoroalkyl, glycols, haloaryl, a negative electrolyte, and a polymer, so long as when R 1 is H, ~ is not H;
R3 and R7 are independently selected from the group
consisting of H, alkyl, perfluoroalkyl, alkylaryl, alkoxyaryl,
alkylcarboxyl, aryl carbonyl, haloalkyl, perfluoroalkyl, glycols, haloaryl, a negative electrolyte, and a polymer; and
R 10 is selected from the group consisting of methyl, alkyl,
aryl, alkylaryl, alkoxyaryl, alkylcarboxyl, aryl carbonyl,
haloalkyl, perfluoroalkyl, perfluoroaryl, glycols, haloaryl, an
oligomer, and a polymer.
In some embodiments of the compound, R 1 and R9 are
each CH 3 or CFy In some embodiments of the compound,
R 1 and R9 are each CH 3 . In some embodiments of the
compound, R 1 and R9 are aryl and perfluoroaryl. In some
embodiments of the compound, R 10 is H, alkyl, or aryl. In
some embodiments of the compound, R 10 is methyl, ethyl,
isopropyl, phenyl, aryl, or perfluoroaryl.
In some embodiments, the compound has the structure of
formula II.

45
(II)

50

55

In some embodiments, the compound has the structure of
formula III.

(II)

60

65
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In some embodiments, the compound has the structure of
formula IV.

8

substituents. These symbols can be any sub stituent, not
limited to those disclosed herein, and when they are defined
to be certain substituents in one instance, they can, m
another instance, be defined as some other substituents.
The term "alkyl" as used herein is a branched or
(IV) 5
unbranched saturated hydrocarbon group of 1 to 24 carbon
atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl,
isobutyl, s-butyl, t-butyl, n-pentyl, isopentyl, s-pentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl, tetrade10 cyl, hexadecyl, eicosyl, tetracosyl, and the like. The alkyl
group can be cyclic or acyclic. The alkyl group can be
branched or unbranched. The alkyl group can also be
In some embodiments, the compound has the structure of
substituted or unsubstituted. For example, the alkyl group
formula V.
can be substituted with one or more groups including, but
15 not limited to, optionally substituted alkyl, cycloalkyl,
alkoxy, amino, ether, halide, hydroxy, nitro, silyl, sulfo-oxo,
(V)
or thiol, as described herein. A "lower alkyl" group is an
alkyl group containing from one to six (e.g., from one to
four) carbon atoms.
20
Throughout the specification "alkyl" is generally used to
refer to both unsubstituted alkyl groups and substituted alkyl
groups; however, substituted alkyl groups are also specifically referred to herein by identifying the specific
substituent(s) on the alkyl group. For example, the term
25 "halogenated alkyl" specifically refers to an alkyl group that
In some embodiments, the compound has the structure of
is substituted with one or more halide, e.g., fluorine, chloformula VI.
rine, bromine, or iodine. The term "alkoxyalkyl" specifically
refers to an alkyl group that is substituted with one or more
alkoxy groups, as described below. The term "alkylamino"
(VI) 30 specifically refers to an alkyl group that is substituted with
one or more amino groups, as described below, and the like.
CH3y
CH3
When "alkyl" is used in one instance and a specific term
such as "alkylalcohol" is used in another, it is not meant to
imply that the term "alkyl" does not also refer to specific
35 terms such as "alkylalcohol" and the like.
This practice is also used for other groups described
herein. That is, while a term such as "cycloalkyl" refers to
both unsubstituted and substituted cycloalkyl moieties, the
In some embodiments, the compound has the structure of
substituted moieties can, in addition, be specifically identiformula VII.
40 fled herein; for example, a particular substituted cycloalkyl
can be referred to as, e.g., an "alkylcycloalkyl." Similarly, a
substituted alkoxy can be specifically referred to as, e.g., a
(VII)
"halogenated alkoxy," a particular substituted alkenyl can
be, e.g., an "alkenylalcohol," and the like. Again, the prac45 tice of using a general term, such as "cycloalkyl," and a
specific term, such as "alkylcycloalkyl," is not meant to
imply that the general term does not also include the specific
term. The term "alkyl" is inclusive of "cycloalkyl."
The term "cycloalkyl" as used herein is a non-aromatic
50 carbon-based ring composed of at least three carbon atoms.
Examples of cycloalkyl groups include, but are not limited
to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl, and the like. The term "heterocycloalkyl" is a type
In some embodiments, the compound has the structure of
of cycloalkyl group as defined above, and is included within
formula VIII.
55 the meaning of the term "cycloalkyl," where at least one of
the carbon atoms of the ring is replaced with a heteroatom
such as, but not limited to, nitrogen, oxygen, sulfur, or
(VIII)
phosphorus. The cycloalkyl group and heterocycloalkyl
group can be substituted or unsubstituted. The cycloalkyl
60 group and heterocycloalkyl group can be substituted with
one or more groups including, but not limited to, optionally
substituted alkyl, cycloalkyl, alkoxy, amino, ether, halide,
hydroxy, nitro, silyl, sulfo-oxo, or thiol as described herein.
In this regard, the term "heterocycle," as used herein
65 refers to single and multi-cyclic aromatic or non-aromatic
In defining various terms such as "R", such terms are used
ring systems in which at least one of the ring members is
herein as generic symbols to represent various specific
other than carbon. Heterocycle includes pyridinde, pyrimi-

),_N+
USN
CH;9 CH;

),_N+
USN
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dine, furan, thiophene, pyrrole, isoxazole, isothiazole, pyrazole, oxazole, thiazole, imidazole, oxazole, including, 1,2,
3-oxadiazole, 1,2,5-oxadiazole and 1,3,4-oxadiazole,
thiadiazole, including, 1,2,3-thiadiazole, 1,2,5-thiadiazole,
and 1,3,4-thiadiazole, triazole, including, 1,2,3-triazole, 1,3,
4-triazole, tetrazole, including 1,2,3,4-tetrazole and 1,2,4,5tetrazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, including 1,2,4-triazine and 1,3,5-triazine, tetrazine,
including 1,2,4,5-tetrazine, pyrrolidine, piperidine, piperazine, morpholine, azetidine, tetrahydropyran, tetrahydrofuran, dioxane, and the like.
The terms "alkoxy" and "alkoxyl" as used herein to refer
to an alkyl or cycloalkyl group bonded through an ether
linkage; that is, an "alkoxy" group can be defined as -OA 1
where A' is alkyl or cycloalkyl as defined above. "Alkoxy"
also includes polymers of alkoxy groups as just described;
that is, an alkoxy can be a polyether such as -OA 1-OA2
or---OA 1 -(OA2 )a-OA3 , where "a" is an integer of from 1
to 200 andA1,A2 , andA3 are alkyl and/orcycloalkyl groups.
The term "alkenyl" as used herein is a hydrocarbon group
of from 2 to 24 carbon atoms with a structural formula
containing at least one carbon-carbon double bond. The term
is include of linear and ring-forming (i.e., cycloakenyl)
groups. Asymmetric structures such as (A 1 A 2 )C=C(A3 A 4 )
are intended to include both the E and Z isomers. This can
be presumed in structural formulae herein wherein an asymmetric alkene is present, or it can be explicitly indicated by
the bond symbol C=C. The alkenyl group can be substituted with one or more groups including, but not limited to,
optionally substituted alkyl, cycloalkyl, alkoxy, alkenyl,
cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, haide, hydroxy,
ketone, azide, nitro, silyl, sulfo-oxo, or thiol, as described
herein.
The term "aryl" as used herein is a group that contains any
carbon-based aromatic group including, but not limited to,
benzene, naphthalene, phenyl, biphenyl, phenoxybenzene,
and the like. The term "aryl" also includes "heteroaryl,"
which is defined as a group that contains an aromatic group
that has at least one heteroatom incorporated within the ring
of the aromatic group. Examples ofheteroatoms include, but
are not limited to, nitrogen, oxygen, sulfur, and phosphorus.
Likewise, the term "non-heteroaryl," which is also included
in the term "aryl," defines a group that contains an aromatic
group that does not contain a heteroatom. The aryl group can
be substituted or unsubstituted. The aryl group can be
substituted with one or more groups including, but not
limited to, optionally substituted alkyl, cycloalkyl, alkoxy,
alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether,
halide, hydroxy, ketone, azide, nitro, silyl, sulfo-oxo, or thiol
as described herein. The term "biaryl" is a specific type of
aryl group and is included in the definition of "aryl." Biaryl
refers to two aryl groups that are bound together via a fused
ring structure, as in naphthalene, or are attached via one or
more carbon-carbon bonds, as in biphenyl.
The term "aldehyde" as used herein is represented by a
formula ----C(O)H. Throughout this specification "C(O)" is a
short hand notation for a carbonyl group, i.e., C=O.
The terms "amine" or "amino" as used herein are represented by a formula NA 1A 2 A 3 , where A 1, A 2 , andA3 can be,
independently, hydrogen or optionally substituted alkyl,
cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl,
aryl, or heteroaryl group as described herein. In specific
embodiments amine refers to any of NH 2 , NH(alkyl),
NH(aryl), N(alkyl) 2 , and N(aryl) 2 .

The term "carboxylic acid" as used herein is represented
by a formula ----C(O)OH.
The term "ester" as used herein is represented by a
formula ---OC(O)A 1 or C(O)OA1, where A 1 can be an
optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as
described herein. The term "polyester" as used herein is
represented by a formula -(A 1 O(O)C-A2 -C(O)O)aor -(A 1 O(O)C-A2 -OC(O))a-, where A 1 and A 2 can be,
independently, an optionally substituted alkyl, cycloalkyl,
alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group described herein and "a" is an integer from 1
to 500. "Polyester" is as the term used to describe a group
that is produced by the reaction between a compound having
at least two carboxylic acid groups with a compound having
at least two hydroxyl groups.
The term "halide," "halogen," or the like refer to the
halogens fluorine, chlorine, bromine, and iodine.
The term "thiol" as used herein is represented by a
formula -SH.
The term "polymer," when used herein to refer to R of the
compounds disclosed herein, includes vinyl polymers,
including but not limited to ethylene, propylene, and styryl
polymers, cyclic alkenes, including for example norbomene,
norbornadiene, cyclopentene, and cyclooctatetraene, acrylates, amines, epoxies, isocyanates, and the like. Also, as
used herein, polymer refers to linear polymers as well as
other arrangements, including for example, dendrimer, star,
and hyper branched polymers. In some embodiments, the
polymer can include phenothiazine as the sole monomer in
a repeating polymer. In some embodiments, the polymer can
include phenothiazine as part of a polymer that contains
more than one repeat unit, e.g., alternating copolymer or
block copolymer. Oligomer, as used herein to refer to R of
the compounds disclosed herein, is made up of a discrete
number of repeat units typically less than about 20, and in
some embodiments, is about five or less repeat units or
monomers.
In some embodiments, the compound can be used as a
redox shuttle.
In some embodiments, the compound can be used as
passivating electrolyte additives for lithium-ion, sodiumion, and other batteries.
In some embodiments, the compound can be used as a
photopolymerization initiator or photoredox catalyst.
In some embodiments, the compound can be used as an
electrode material in a battery including non-aqueous redox
flow batteries.
As used here, the term "redox shuttle" refers to an
electrochemically reversible compound that can become
oxidized at a positive electrode of a battery, migrate to a
negative electrode of the battery, become reduced at the
negative electrode to reform the unoxidized/less-oxidized
shuttle species, and migrate back to the positive electrode. A
redox shuttle can be an electroactive compound, which can
be heterocyclic. A redox shuttle can protect against overcharging.
The presently-disclosed subject matter includes a
rechargeable battery. In some embodiments, the rechargeable battery includes a negative electrode, a positive electrode, and an electrolyte that includes a compound as
disclosed herein. In some embodiments, the positive electrode is immersed in the electrolyte. In some embodiments,
the electrolyte further comprises a charge-carrying medium.
In some embodiments, the electrolyte further includes a
lithium salt.

5

10

15

20

25

30

35

40

45

50

55

60

65

US 10,854,911 B2
11

12

In some embodiments, the rechargeable battery is a
rechargeable lithium-ion battery, which includes a highvoltage cathode, a negative electrode, an electrolyte comprising a charge-carrying medium and a lithium salt, and a
redox shuttle comprising a compound as disclosed herein.
The term "electrolyte" is well understood to those of
ordinary skill in the art and provides a charge-carrying
pathway between the negative electrode and the positive
electrode. The electrolyte can include a charge-carrying
medium and a lithium salt. The electrolyte can also include
a redox shuttle.
In some embodiments, the battery makes use of a compound/redox shuttle at a concentration of about 0.05-0.1 M.
In some embodiments, the battery makes use of a compound/redox shuttle having a solubility of about 0.5 M or
greater.
The term "negative electrode" is well understood to those
of ordinary skill in the art and refers to one of a pair of
electrodes that, under normal circumstances and when the
battery/cell is fully charged, has the lowest potential. The
negative electrode that can be used in connection with the
presently-disclosed subject matter is not particularly limited
and can be generally selected from those known in the art,
for example, a graphitic anode.
The term "positive electrode" is well understood to those
of ordinary skill in the art and refers to one of a pair of
electrodes that, under typical circumstances, and when the
battery/cell is fully charged, will have the highest potential
that it can achieve under normal operation.
As passivating electrolyte additive is a composition added
that can stabilize the surface of anode, typically by forming
a passivation film.
A photopolymerization initiator is a chemical species that
upon exposure to light (for example, ultraviolet or visible
spectrum) produces a reactive species that can react with a
composition, and changes the composition in one or more
properties. An exemplary photopolymerization initiator can,
for example, upon exposure to light, react with a polymerizable composition to generate a cross-linked polymer.
A photoredox catalyst uses light to facilitate a chemical
reaction by mediating a transfer of electrons between chemical compounds. The photoinduction of electron transfer of
the catalysts allows for the activation of substrates that do
not readily absorb the energy of light by themselves.
As noted herein, the presently-disclosed subject matter
includes rechargeable batteries in which the positive electrode is a high-voltage cathode. Examples of high-voltage
cathodes include, but are not limited to LiFePO4 (LFP),
LiMn2 O4 (LMO), LiCoO 2 (LCO), LiNi 113 Mn 113 Co 113 O 2
(NMC), and LiNi 0 8 Co 0 15Al 0 05 0 2 (NCA). A high-voltage
cathode is one that can be said to have an end-of-charge
potential of about 4.0 V or greater. Such high-voltage
cathodes benefit from redox shuttles that oxidize at potentials of at least about 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, or 4.7
to about 4.8 Vas compared to Li/Li+.
In some embodiments of the presently-disclosed subject
matter, the battery makes use of a compound that oxidizes at
a potential of about 3.7 V to about 5.0 V as compared to
Li/Li+. In some embodiments of the presently-disclosed
subject matter, the battery makes use of a compound that
oxidizes at a potential of about 4.0 V to about 4.8 V as
compared to Li/Li+. In some embodiments, the compound
oxidizes at a potential of about 4.2 V to about 4.5 V. In some
embodiments, the compound oxidizes at a potential of about
4.2 V to about 4.3 V.
The presently-disclosed subject matter is further inclusive
of an article that includes a battery as disclosed herein.

Batteries connected in series can be particularly vulnerable to overcharge. The presently-disclosed subject matter is
inclusive of an array that includes two or more batteries as
disclosed herein. In some embodiments, the array includes
two or more batteries connected in a series.
While the terms used herein are believed to be well
understood by those of ordinary skill in the art, certain
definitions are set forth to facilitate explanation of the
presently-disclosed subject matter.
Unless defined otherwise, all technical and scientific
terms used herein have the same meaning as is commonly
understood by one of skill in the art to which the invention(s)
belong.
All patents, patent applications, published applications
and publications, databases, websites and other published
materials referred to throughout the entire disclosure herein,
unless noted otherwise, are incorporated by reference in
their entirety.
Where reference is made to a URL or other such identifier
or address, it understood that such identifiers can change and
particular information on the internet can come and go, but
equivalent information can be found by searching the internet. Reference thereto evidences the availability and public
dissemination of such information.
As used herein, the abbreviations for any protective
groups, amino acids and other compounds, are, unless
indicated otherwise, in accord with their common usage,
recognized abbreviations, or the IUPAC Nomenclature.
Although any methods, devices, and materials similar or
equivalent to those described herein can be used in the
practice or testing of the presently-disclosed subject matter,
representative methods, devices, and materials are described
herein.
Following long-standing patent law convention, the terms
"a", "an", and "the" refer to "one or more" when used in this
application, including the claims. Thus, for example, reference to "a cell" includes a plurality of such cells, and so
forth.
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions,
and so forth used in the specification and claims are to be
understood as being modified in all instances by the term
"about". Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this specification and
claims are approximations that can vary depending upon the
desired properties sought to be obtained by the presentlydisclosed subject matter.
As used herein, the term "about," when referring to a
value or to an amount of mass, weight, time, volume,
concentration or percentage is meant to encompass variations of in some embodiments ±20%, in some embodiments
±10%, in some embodiments ±5%, in some embodiments
±1 %, in some embodiments ±0.5%, and in some embodiments ±0.1 % from the specified amount, as such variations
are appropriate to perform the disclosed method.
As used herein, ranges can be expressed as from "about"
one particular value, and/or to "about" another particular
value. It is also understood that there are a number of values
disclosed herein, and that each value is also herein disclosed
as "about" that particular value in addition to the value itself.
For example, if the value "10" is disclosed, then "about 10"
is also disclosed. It is also understood that each unit between
two particular units are also disclosed. For example, if 10
and 15 are disclosed, then 11, 12, 13, and 14 are also
disclosed.
As used herein, "optional" or "optionally" means that the
subsequently described event or circumstance does or does
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not occur and that the description includes instances where
said event or circumstance occurs and instances where it
does not. For example, an optionally variant portion means
that the portion is variant or non-variant.
The presently-disclosed subject matter is further illustrated by the following specific but non-limiting examples as
set forth by the present inventors. The following examples
may include compilations of data that are representative of
data gathered at various times during the course of development and experimentation related to the present invention.

At the outset of the investigation, density functional
theory (DFT) calculations were performed at the B3LYP/6311 G(d,p) level to predict molecular geometries in the
5

ti cal ionization potentials (IPs) of various substituted phenothiazines.
10

EXAMPLES
Example 1

neutral and radical-cation states and the adiabatic and ver-

15

Inspired by studies of molecular strain, the strategic
placement of substituents on the phenothiazine core was

The neutral geometries of EPT, 3,7-DMeEPT, and 1,9DMeEPT are quite similar, with the butterfly angles showing
little variation (139-143°). However, as radical cations, EPT
and 3,7-DMeEPT are significantly more planar(171°) than
1,9-DMeEPT)(157° (Table 1); note that 180° represents a
fully planar phenothiazine. Similar trends are noted for the
other 3,7- and 1,9-substituted phenothiazines in the series.
TABLE 1

Adiabatic ionization potentials (IP), half-wave first oxidation potentials (Eu2 • 10 ) vs.
Cp 2 Fe+/O, and neutral and radical cation butterfly angles.
Butterfly Angles (
Compound
MPT
EPT
iPrPT
tBuPT
PhPT
3,7-DMeEPT
3,7-BCF3EPT
1,9-DMeEPT
1,9-BCF3EPT
1,9-DMeiPrPT
1,9-DMePhPT

IP (eV)lal
6.58
6.48
6.52
6.67
6.34
6.24
7.06
6.68
7.21
6.76
6.85

El/2 +lo (V)lhl Neutral
0.31 [e]
0.27
o.33[e]
0.53[e]
0.26[e]
0.13[1]
0.61[1]
0.55
0.68
0.86[c]

143.4
138.7
142.6
134.2
149.5
138.8
139.7
143.1
141.8
132.5
132.4

(143.7jl''l
(136.8)[dl
(137.9)[e]
(135.0jlel
(162.3)[e]
(149.3)[1]
(144.5-152.l)[gl
(146.5)
(134.1)
(134.9)

0

)[a]

Radical Cation
165.2 (177.8)
171.4 (173.8)
160.7
148.3
180.0
171.1
171.1 (164.5)[gl
156.6
159.0
147.5
137.2

[a]DFT calculations at the B3LYP/6-31 l(d,p) level of theory; X-ray crystallographic values in parentheses.
[blcy performed with 1.6 mM in O.lM nBu4NPF6/DCM at 100 mV/s.
[cloxidation was irreversible.
[d]Reference[II]_

[e1Reference[7b]_
[f]Reference[9dJ.

[g]Multiple molecules present in asymmetric unit, reference[ 12 1.

investigated for use to tune molecular redox characteristics
through geometric constraints, with minimal impact of the
substituent electronic effects. Deliberate incorporation of
substituents around the periphery of the phenothiazine core
was also tested for ability to disrupt the relaxation of the
radical-cation state, thereby increasing the oxidation potential when compared to the unsubstituted system.
Derivatives of N-substituted phenothiazines where substituents were incorporated at positions ortho to the nitrogen
atom (1 and 9 positions) were evaluated for capability to
prevent planarization of the oxidized species through steric
interactions with the N-alkyl group.
The electrochemical characteristics of these derivatives
were compared to a parent compound with only an N
substituent, and to derivatives where the same substituents
are incorporated at positions para to the nitrogen atom (3 and
7 positions) so that planarization in the oxidized state
remains possible and the full electronic effects of the substituents would be in play. For the sake of clarity, these
Examples will focus discussion on the N-ethyl derivatives,
where EPT is the parent, 1,9-DMeEPT the crowded derivative, and 3,7-DMeEPT the uncrowded analogue (FIG. 1).
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A series of phenothiazine derivatives have been studied,
where the geometry of the oxidized (radical-cation) state
tends to be planar, while the neutral ground state is bent. [7 l
In particular, for N-substituted phenothiazines (FIG. 1, left),
the present inventors observed a correlation in the degree of
molecular bending (referred to as the "butterfly angle") of
the radical-cation geometry and the ease of oxidation: From
ethyl to iso-propyl to tert-butyl (EtPT, iPrPT, tBuPT), the
increased substituent size led to a larger radical-cation
butterfly angle and higher-potential oxidation events (Table
1). Importantly, this effect is opposite to what one would
predict based on the Hammett constants of the substituents,
suggesting that preventing planarization in radical cations
may raise oxidation potentials, regardless of the substituent's Hammett constant.
DFT calculations predict 3,7-DMeEPT to have an adiabatic IP 0.24 eV smaller than EPT, consistent with measured
oxidation potentials[9 cJ and expectations based on the electron-donating capability of a methyl group. However, 1,9DMeEPThas an IP 0.20 eVlargerthan EPT (Table 1). Thus,
for the two DMeEPT constitutional isomers, we observe a
difference in IP of 0.44 eV. The IP trends are similar for
3,7-BCF3EPT and 1,9-BCF3EPT, with 1,9-BCF3EPT having a largerIP, though the IP range is smaller (0.15 V). These
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results showcase the considerable impact that steric crowding of the radical-cation state can have in order to increase
the IP.

TABLE 4

Similar trends are observed for the vertical IPs (Table 2).
Notably, the relaxation energy (!,) in the radical-cation
potential energy surface is smaller for 1,9-DMeEPT (at 0.27
eV) than for EPT and 3,7-DMeEPT (both at 0.40 eV),
signifying the impact of the methyl groups at the 1 and 9
positions in limiting radical cation relaxation to a more
planar configuration. Moreover, the vertical IPs for EPT and
1,9-DMeEPT are quite similar (differing by 0.07 eV), while
that of3,7-DMeEPT is much smaller than EPT (by 0.23 eV),
revealing the differences in the electronic impact of methyl
substituents in the 1 and 9 vs. 3 and 7 positions. Potential
energy surfaces displaying these differences in terms of the
adiabatic and vertical IPs and relaxation energies are represented in FIG. 2.

D 1 _, D2 vertical transition energies, oscillator strengths (f), and electronic
configurations for select phenothiazine derivatives as determined with
TDDFT at tbe B3LYP/6-311G(d,p) level oftbeory.
5

Radical Cation

Compound
10 EPT
3,7-DMeEPT
1,9-DMeEPT
15

1,9-DMePhPT

20

TABLE 2
Select frontier molecular orbital energies, vertical and
adiabatic ionization potentials (VIP and AIP, respectively), and
relaxation energies in the radical-cation potential energy

25

surface (}1.,1p) for select phenothiazine derivatives as
determined at tbe B3LYP/6-311G(d, p) level oftbeory.

HOMO-!

HOMO

LUMO

AIP

VIP

Compound

(eV)

(eV)

(eV)

(eV)

(eV)

(eV)

MPT

-6.30

-5.27

-0.61

6.58

6.87

0.29

EPT

-6.26

-5.30

-0.56

6.48

6.88

0.40

iPrPT

-6.23

-5.22

-0.57

6.52

6.77

0.25

tBuPT

-6.20

-5.39

-0.55

6.67

6.93

0.25

PhPT

-6.24

-5.16

-0.91

6.34

6.68

0.33

3,7-DMeEPT

-6.12

-5.15

-0.46

6.24

6.65

0.40

3,7-BCF3EPT

-6.94

-5.96

-1.44

7.06

7.49

0.43

1,9-DMeEPT

-6.14

-5.40

-0.51

6.68

6.95

0.27

1,9-BCF3EPT

-6.83

-5.96

-1.40

7.21

7.52

0.31

1,9-DMeiPrPT

-6.35

-5.69

-0.56

6.76

7.25

0.49

1,9-DMePhPT

-6.08

-5.55

-0.76

6.85

7.00

0.15

30
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TABLE 3
50
S0

S 1 vertical transition energies, oscillator strengths (f), and electronic
configurations for select phenothiazine derivatives as determined with
TDDFT at tbe B3LYP/6-311G(d,p) level oftbeoa.
_,

Neutral
55
Compound
EPT
3,7-DMeEPT
1,9-DMeEPT
1,9-DMeiPrPT
1,9-DMePhPT

So_, S1
(nm, eV)

322
(3.85)
322
(3.85)
310
(4.00)
287
(4.33)
309
(4.02)

f

Configuration

0.0003

HOMO -

LUMO (98%)

0.0004
0.0052

HOMO HOMO HOMO -

LUMO (5%)
LUMO + 1 (92%)
LUMO (97%)

0.0148

HOMO -

LUMO (91%)

0.0327

HOMO -

LUMO (98%)

1,9-DMeiPrPT

60
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D1 _, D2
(nm, eV)
773
(1.60)
755
(1.64)
1024
(1.21)
1127
(1.10)
1564
(0.79)

f

Configuration

0.0146

HOMO-! -

SOMO (98%)

0.0112

HOMO-! -

SOMO (98%)

0.0105

HOMO-! -

SOMO (99%)

0.0098

HOMO-! -

SOMO (99%)

0.0275

HOMO-! -

SOMO (99%)

With computational results in hand that supported our
hypothesis, 1,9-DMeEPT and related N-iso-propyl (1,9DMeiPrPT) and N-phenyl (1,9-DMePhPT) derivatives
(FIG. 1) were prepared for further study. Solid-state butterfly
angles show good agreement with DFT calculations (Table
1). Importantly, the trends in oxidation potentials from CV
experiments (FIG. 3) validated our hypothesis and computational results. Unlike 3,7-DMeEPT, which is more easily
oxidized than EPT (by 0.13 V), 1,9-DMeEPT is harder to
oxidize than EPT (by 0.28 V). Moreover, as the size of the
radical-cation butterfly angle within the series of 1,9-dimethyl-substituted phenothiazines, the oxidation potentials
increase further. Of the three 1,9-dimethyl-substituted
derivatives, 1,9-DMePhPT has the highest oxidation potential. Notably, this trend does not follow that of the solely
N-substituted equivalents (iPrPT is harder to oxidize than
both EPT and PhPT),[ 7 bJ though within each series of three
compounds, the oxidation potentials follow the same trends
as the calculated adiabatic IPs and radical-cation butterfly
angles. Furthermore, scans of the full electrochemical window (FIG. 4) show that reduction events remain inaccessible
throughout the series, with solvent reduction occurring
before a reduction event could be observed.
UV-vis absorption spectroscopy was used to explore
electronic transitions in the neutral and radical-cation states.
While the absorption profiles of neutral EPT and 3,7DMeEPT are nearly identical, the absorption onsets of the
1,9-dimethyl-substituted derivatives are slightly blue-shifted
(FIG. Sa). These changes in energy, although small, are
consistent with trends in the energy of the S0 ----;,S 1 transition
energy determined by time-dependent DFT (TD-DFT) calculations (Table 2). UV-vis spectra of the radical cations,
generated by chemical oxidation, further reflect differences
in the oxidized species (FIG. Sb). The absorption spectra of
the radical cations of EPT and 3,7-DMeEPT show profiles
consistent with the radical cations of several phenothiazine
derivatives prepared in our laboratory: intense absorption
features between 500-600 nm and low-energy, low-intensity
bands between 650-950 nmP 6 •13 l By contrast, the analogous absorption features for the 1,9-disubstituted derivatives
occur at lower energies. These trends in transition energies
are confirmed by TD-DFT calculations (Table 2). Our results
suggest that variation in placement of methyl groups affects
the electronic gap between the HOMO-I and HOMO (using
the nomenclature of the neutral species), which in tum
influences the D 1 ----;,D 2 transition of the radical cation that is
predominately
HOMO-] --;,SOMO
(singly-occupied
molecular orbital) in nature. From DFT calculations, the
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HOMO of EPT and 1,9-DMeEPT are nearly isoenergetic,
while that of3,7-DMeEPT is energetically destabilized; this
is consistent with the trends of the computed vertical IPs,
confirming the validity of a Koopmans' theorem [14l (Janak' s
theorem[ 15 l in the context of DFT) estimate of the verticals
IP based on the HOMO energies. However, the HOMO-I of
3,7-DMeEPT and 1,9-DMeEPT are of similar energy and
energetically destabilized when compared to EPT, revealing
the comparable electronic impact of the methyl groups on
the HOMO-I regardless of the methyl group location on the
phenothiazine. The combination of these effects results in a
smaller HOMO-I to HOMO energy gap for 1,9-DMeEPT,
which is found here to translate to a smaller first-excitedstate transition energy of the radical cation.
In summary, by positioning traditionally electron-donating substituents in close proximity to the N substituent, the
relaxation of the phenothiazine radical-cation state was
disrupted with increased the oxidation potentials relative to
their counterparts that are able to fully relax. This approach
offers a strain-induced modulation of electrochemical properties orthogonal to conventional tuning by substituent character. The aim is to identify new organic materials with
higher oxidation potentials while limiting access to reduction events by disrupting relaxation pathways in fused-ring
systems.

mmol), urea (0.90 g, 14.9 mmol), sodium tert-butoxide (6.62
g, 68.9 mmol), and anhydrous dioxane (70 mL). The reaction mixture was sparged with N 2 for 15 min. Bis(dibenzylideneacetone)palladium(0) (0.092 g, 0.15 mmol) and
tri-tert-butylphosphonium tetrafluoroborate (0.087 g, 0.30
mmol) were added and after sparging with Na for an
additional 10 min, the reaction vessel was sealed with a
PTFE screw cap. The pressure vessel was immersed in an oil
bath heated to 100° C. and was stirred overnight. The
reaction mixture was then removed from the oil bath and
allowed to cool to room temperature. Water was added to the
reaction mixture, and the product was extracted with ethyl
acetate, washed with brine, and dried over magnesium
sulfate (MgSO4 ). The organic layer was filtered to remove
solids and was concentrated by rotary evaporation. The
crude product was passed through a short pad of alumina,
eluting with hexanes to afford the product as a pale yellow
oil (2.50 g, 84%). 1 H NMR (400 MHz, CDC1 3 ) Ii 7.17 (d,
J=7.4 Hz, 2H), 7.09 (t, J=7.6 Hz, 2H), 6.97 (d, J=8.0 Hz,
2H), 6.88 (t, J=7.4 Hz, 2H), 5.11 (s, lH), 2.24 (s, 6H). 13 C
NMR (100 MHz, CDC1 3 ) 5142.0, 130.9, 127.6, 126.9,
121.5, 118.4, 17.9.
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S, cat. 12
ODCB
180° C., 8 h

Example 2
2-Bromotoluene was purchased from Oakwood Products.
Urea, bromoethane, 2-bromopropane, tetrabutylammonium
hexafluorophosphate,
tris(4-bromophenyl)aminium
hexachloroantimonate, anhydrous toluene, and anhydrous
p-dioxane were purchased from Sigma Aldrich. Phenothiazine, sodium hydride (60% dispersion in mineral oil),
bis(dibenzylideneacetone)palladium(0), sodium tert-butoxide, sulfur, iodine, o-dichlorobenzene (ODCB), anhydrous
dichloromethane (DCM), anhydrous tetrahydrofuran, anhydrous N,N-dimethylformamide (DMF), and magnesium sulfate were obtained fromAcros Organics. Tri-tert-butylphosphonium tetrafluoroborate was obtained from Oxchem.
Silica gel and neutral alumina used for colunm chromatography were purchased from Silicycle and Sorbent Technologies, respectively. Ethyl acetate, hexanes, and diethyl ether
were purchased from VWR. Solvents used for NMR spectroscopy were obtained from Cambridge Isotope Laboratones.
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1,9-Dimethylphenothiazine (1,9-DMePT)
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Example 3
N-Ethylphenothiazine 16 and N-ethyl-3,7-dimethylphenothiazine 1 7 were prepared as previously reported.

50

urea
Pd(dba)i
tBu3P•HBF4
NaOtBu

55

dioxane,
reflux, o/n

60

Bis(o-tolyl)amine
This compound was synthesized by modifying a previously reported procedure. 18 To an oven-dried 350 mL pressure vessel were added 2-bromotoluene (3.62 mL, 30.1

65

This compound was synthesized following a slightly
modified version of a reported procedure. 19 To an oven-dried
pressure tube cooled under Na, bis(o-tolyl)amine (2.70 g,
13.7 mmol), sulfur (1.09 g, 34.2 mmol), iodine (0.0510 g,
0.402 mmol), and ODCB (2 mL) were added. The pressure
tube was sealed with a Teflon cap, and the reaction mixture
was immersed in an oil bath heated to 180° C. for 8 h. After
removing the reaction flask from the oil bath, the reaction
mixture was allowed to cool to room temperature. It was
then diluted with ethyl acetate and water, and the precipitate
was removed via filtration. The organic layer was separated
from the aqueous layer and washed with brine. The organic
layer was then dried over MgSO4 , filtered, and concentrated
by rotary evaporation. The resulting crude material was
purified by colunm chromatography over neutral alumina
using a gradient of hexanes and ethyl acetate to elute the
product, which was crystallized from ethanol (0.81 g, 26%).
1
H NMR (400 MHz, CD 3 CN) ll 6.94 (d, J=7.7 Hz, 2H), 6.85
(d, J=7.7 Hz, 2H), 6.76 (t, J=7.5 Hz, 2H), 6.02 (br, lH), 2.25
(s, 6H). 13 C NMR (100 MHz, CD3CN) 5141.2, 130.1,
125.4, 123.8, 123.3, 118.9, 17.1. Anal. calcd. for C 14H 13 NS
C, 73.97; H, 5.76; N, 6.16. Found C, 73.67; H, 5.79; N, 6.06.

HX)
CX
N

~

s

~ I

1) NaH, DMF/THF
60° C., 10 min
2) EtBr, 60° C., o/n
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-continued

The organic layer was separated from the aqueous layer,
washed with water and brine, dried over MgSO4 , and
concentrated by rotary evaporation. The crude material was
purified by colunm chromatography over silica gel using
hexanes as the eluent, then crystallized from aqueous ethanol, yielding the product as a white crystalline solid (0.25 g,
42%). 1 H NMR (400 MHz, CD 3 CN) Ii 7.22 (dd, J=7.9, 0.6
Hz, 2H), 7.17 (m, 2H), 7.05 (t, J=7.6 Hz, 2H), 3.79 (heptet,
1=6.4 Hz, lH), 2.51 (s, 6H), 1.00-0.92 (d, 6H). 13 C NMR
(100 MHz, CD 3 CN) Ii 145.2, 138.9, 137.2, 130.0, 126.22,
126.18, 53.5, 22.5, 19.1. GC-MS: m/z 269 (8%), 226
(100%). Anal. calcd. for C 18 H 21 NS C, 75.79; H, 7.11; N,
5.20. Found C, 75.52; H, 7.12; N, 5.18.

D~
USN
Synthesis of N-ethyl-1,9-dimethylphenothiazine
(1,9-DMeEPT)
In an oven-dried 50 mL round-bottomed flask equipped
with a reflux condenser under a Na atmosphere, 1,9-dimethylphenothiazine (0.542 g, 2.39 mmol) was dissolved in a
solution of anhydrous DMF (8 mL) and anhydrous THF (8
mL). Sodium hydride (0.202 g, 60 wt.% in mineral oil, 5.05
mmol) was added at room temperature, and the reaction was
stirred for 10 min. Bromoethane (0.90 mL, 12 mmol) was
added to the reaction mixture, which was then heated to
reflux in an oil bath set at 90° C. for 12 h. The reaction
mixture was cooled to room temperature and quenched with
ice water. The reaction mixture was then extracted with ethyl
acetate, and the organic layer was washed with brine and
dried over MgSO4 . The organic extracts were filtered and
concentrated by rotary evaporation. The resulting organic
residue was purified by silica gel colunm chromatography
using a gradient of 0-10% ethyl acetate in hexanes as eluent
to afford 0.142 g (23%) of a white solid. The purified product
was further crystallized from aqueous ethanol to afford
white crystals. 1 H NMR (400 MHz, CDCl 3 ) Ii 7 .07 (d, J=7 .9
Hz, 4H), 6.97 (dd, J=8.0, 7.1 Hz, 2H), 3.45 (q, J=7.1 Hz,
2H), 2.41 (s, 6H), 1.07 (t, J=7.2 Hz, 3H). 13 C NMR (100
MHz, CDCl 3 ) Ii 144.6, 134.9, 134.6, 129.7, 125.2, 125.1,
77.8, 77.7, 77.5, 77.2, 50.0, 18.9, 14.7. GC-MS: m/z 255
(24%), 226 (100%). Anal. calcd. for C 16 H 17 NS C, 75.25; H,
6.71; N, 5.38. Found C, 74.95; H, 6.73; N, 5.42.
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l)NaH,DMF
0° C.,5 min
2) iPrBr, rt, o/n
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1,9-Dimethyl-N-iso-propylphenothiazine
(1,9-DMeiPrPT)
To an oven-dried 25 mL round-bottomed flask cooled
under Na was added 1,9-dimethylphenothiazine (0.50 g, 2.2
mmol) and anhydrous DMF (5 mL). The solution was
immersed in an ice-water bath, after which sodium hydride
(0.116 g, 60 wt. % in mineral oil, 4.84 mmol) was added.
After stirring the suspension for 5 min, 2-bromopropane
(0.81 g, 6.59 mmol) was added into the reaction mixture.
The reaction was allowed to warm to room temperature and
was stirred for 12 h. Ice was added to the reaction mixture,
and the resulting precipitate was dissolved in diethyl ether.
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HX)
CX
N

~

s

~

I

PhBr, Pd(dba)2
tBu3P•HBF4, NaOtBu

toluene, reflux, o/n

9

~N~

USN
1,9-Dimethy1-N-pheny lphenothiazine
(1,9-DMePhPT)
To an oven-dried 15 mL pressure vessel with stir bar,
1,9-dimethylphenothiazine (0.45 g, 2.0 mmol), bromobenzene (1.57 g, 10.0 mmol), and anhydrous toluene (5 mL)
were added, and the resulting solution was sparged with Na
for 10 min. Sodium tert-butoxide (0.29 g, 3.0 mmol),
bis(dibenzylideneacetone)palladium(0) (0.028 g, 0.050
mmol), and tri-tert-butylphosphonium tetrafluoroborate
(0.030 g, 0.10 mmol) were added, and the reaction was
sealed with a PTFE screw cap. The reaction flask was
immersed in an oil bath heated to 120° C. for 36 h with
stirring, after which the flask was removed from the oil bath
and allowed to cool to room temperature. Water was added
to the reaction mixture, and the product was extracted from
the aqueous layer with diethyl ether. The combined organic
extracts were washed with brine, dried over MgSO4 , filtered
to remove solids, and concentrated by rotary evaporation.
The crude product was purified by silica gel colunm chromatography using 0.5% diethyl ether in cyclohexane to
afford the desired product as a white solid (153 mg, 25%).
The product was crystallized using aqueous ethanol to afford
a white crystalline solid. 1 H NMR (400 MHz, CDCl 3 ) Ii 7 .39
(d, J=7.6 Hz, 2H), 7.28 (t, J=3.9 Hz, 3H), 7.17 (dt, J=16.0,
8.0 Hz, 4H), 6.85 (t, J=7.3 Hz, lH), 6.42 (d, J=8.1 Hz, 2H),
2.51 (s, 6H). 13 C NMR (100 MHz, CDCl 3 ) Ii 144.9, 141.3,
138.0, 137.5, 129.1, 129.0, 126.7, 126.5, 119.6, 113.1, 77.5,
77.4, 77.2, 76.8, 18.4. GC-MS: m/z 226 (77%), 303 (100%).
Anal. calcd. for C 20 H 17 NS: C, 79.17; H, 5.65; N, 4.62.
Found C, 79.26; H, 5.62; N, 5.72.
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SADAB S. 25 All structures were solved using SHELXT 26
and refined with SHELXL-2014/7. 27 Hydrogen atoms were
included using the riding-model approximation. Non-hydrogen atoms were refined with anisotropic displacement
parameters. Atomic scattering factors were taken from the
International Tables for Crystallography, vol. C. 28 Reference
is made to FIGS. 7-10.
Example 6

10

15

N-ethyl-1,9-dimethyl-3, 7-bis(trifluoromethyl)phenothiazine (l,9-DMe-3,7 BCF3EPT)
1,9-DMe-3,7-DBrEPT (1.25 g, 3.03 mmol) and Copper(i)
iodide (4.61 g, 24.2 mmol) were added in to an oven dried
100 mL pressure vessel under a Na atmosphere. The pressure vessel was transferred to an argon filled glove box, then
potassium trifluoroacetate (2.76 g, 18.2 mmol) and cesium
fluoride (0.99 g 6.50 mmol) were added into the pressure
vessel and removed it from the glove box. N-Methylpyrrolidinone (NMP) (44 mL) and 1,3-Dimethyl-2-imidazolidinone (10 mL) were added under Na atmosphere to the
reaction mixture and purged with Na for 10 min in preheated
(90° C.) oil bath. Pressure vessel was sealed and increased
the temperature up to 180° C. stirred for 48 h. Reaction
mixture was cooled to room temperature, diluted with ethyl
acetate and filtered through celite. Then water was added to
the filtrate and organic product was extracted with ethyl
acetate. The combined organic layers were washed with
brine and dried over MgSO4 . The organic extracts were
filtered and concentrated by rotary evaporation. The resulting organic crude was purified by silica gel column chromatography using a gradient of 0-2% ethyl acetate in
hexanes as eluent, yielding the product as a white crystalline
solid (0.6 g, 48%). 1 H NMR (400 MHz, DMSO-d 6 ) Ii
7.58-7.51 (m, 4H), 3.57 (q, J=7.1 Hz, 2H), 2.43 (s, 6H), 0.99
(t, J=7.1 Hz, 3H). 19 F NMR (400 MHz, Chloroform-d)
ll-65.39 (s, 6H). GCMS: m/z 391 (23%), 362 (100%), 330
(8%). Anal. Calcd. for C 18 H 15 F 6 NS: C, 55.24; H, 3.86; F,
29.13; N, 3.58; S, 8.19. Found C, 55.04; H, 4.05; N, 3.60.
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Example 4
Computational Studies. All density functional theory
(DFT) calculations were performed using the Gaussian09
(Revision A.02b) software suite. 20 Geometry optimizations
of the neutral and radical-cation states were carried out with
the B3LYP functional 21 •22 and 6-311 G(d,p) basis set. Frequency analyses of all (fully relaxed) optimized geometries
were performed to ensure that the geometries were energetic
minima. Reference is made to FIG. 6.

50

Example 7
UV-Visible Spectroscopy. UV-vis spectra were obtained
using optical glass cuvettes (Starna) with 1 cm path length
on an Agilent 8453 diode array spectrophotometer. Spectra
of neutral compounds were obtained in DCM at concentrations of 14 µM. Spectra of radical cations were obtained in
anhydrous DCM by mixing 0.5 mL of a 0.5 mM solution of
TBPASbCl 6 in DCM with 2.0 mL of a solution that was 2.5
mM radical cation. The resultant solution contained 0.1 mM
radical cation and 1.9 mM neutral analyte. After the cuvette
was capped and mixed, UV-vis spectra were recorded immediately.
All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication,
patent, or patent application was specifically and individually indicated to be incorporated by reference, including the
references set forth in the following list:
REFERENCES
1. a) L. P. Hanrmett, J. Am. Chem. Soc.1937, 59, 96-103; b)
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Example 5
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X-Ray Crystallography. X-ray diffraction data were collected on either a Nonius kappaCCD diffractometer (MoKD
X-rays: 1,9-DMeiPrPT) or a Bruker-Nonius XS Proteum
diffractometer (CuKD X-rays:
1,9-DMeEPT, 1,9DMePhPT). Raw data were integrated using the DenzoSMN package 23 (kappaCCD) or by APEX2 (XS Proteum). 24
Scaling and merging for all datasets were performed using

Electrochemical Analysis. Cyclic voltammetry (CV)
experiments were performed with a CH Instruments 600D
potentiostat using a three-electrode system with glassy carbon as the working electrode, freshly anodized Ag/AgCl as
the reference electrode, and a Pt wire as the counter electrode. Each solution contained 1.6 mM analyte and 0.1 M
TBAPF 6 in DCM. Voltammograms were recorded at a scan
rate of 100 mV/s. Oxidation potentials are reported relative
to ferrocenium/ferrocene )(Cp 2 Fe+/O. To calibrate samples,
ferrocene or decamethylferrocene was used as an internal
reference.
Voltammograms containing the internal reference---either
ferrocene or decamethylferrocene-in which the first oxidation event of the phenothiazine derivative was accessed
are shown in FIG. 11.
Voltammograms of the phenothiazines (note: no internal
reference in these scans) are shown in FIG. 4 in which the
full solvent window was scanned.
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5

10

15

20

25

30

35

40

45

We claim:
1. A compound according to the formula:
50

55

60

65

wherein
R 1 and R 9 are independently selected from the group
consisting of H, alkyl, aryl, perfluoroaryl, perfluoroalkyl, alkylaryl, alkoxyaryl, alkylcarboxyl, aryl
carbonyl,
haloalkyl,
perfluoroalkyl,
glycols,
haloaryl, a negative electrolyte, and a polymer, so
long as when R 1 is H, R 9 is not H;
R 3 and R 7 are independently selected from the group
consisting of H, alkyl, perfluoroalkyl, alkylaryl,

US 10,854,911 B2

25

26

alkoxyaryl, alkylcarboxyl, aryl carbonyl, haloalkyl,
perfluoroalkyl, glycols, haloaryl, a negative electrolyte, and a polymer; and
R 10 is selected from the group consisting of aryl,
alkylaryl, alkoxyaryl, aryl carbonyl perfluoroaryl,
glycols, haloaryl, an oligomer, and a polymer.

or
a compound according to the formula:

5

2. The compound according to claim 1, selected from the
group consisting of:
10

wherein
R 1 and R9 are independently selected from the group
consisting of alkyl, aryl, perfluoroaryl, perfluoro15
alkyl, alkylaryl, alkoxyaryl, alkylcarboxyl, aryl carand
bonyl, haloalkyl, perfluoroalkyl, glycols, haloaryl, a
negative electrolyte, and a polymer;
R3 and R7 are independently selected from the group
consisting of H, alkyl, perfluoroalkyl, alkylaryl,
20
alkoxyaryl, alkylcarboxyl, aryl carbonyl, haloalkyl,
perfluoroalkyl, glycols, haloaryl, a negative electrolyte, and a polymer; and
R 10 is selected from the group consisting of aryl,
alkylaryl, alkoxyaryl, aryl carbonyl, perfluoroaryl,
25
haloaryl, an oligomer, and a polymer.
6. A rechargeable battery comprising:
a
negative electrode;
3. The compound according to claim 1, wherein R 10 is
a positive electrode; and
aryl.
30
an electrolyte comprising the compound of claim 5.
4. The compound according to claim 1, wherein R 10 is
7. The battery of claim 6, wherein the positive electrode
phenyl.
is immersed in the electrolyte.
5. A compound according to the formula:
8. The battery of claim 6, wherein the electrolyte further
comprises a charge-carrying medium and a lithium salt.
35
9. The battery of claim 6, wherein the positive electrode
comprises a high-voltage cathode.
10. The battery of claim 9, wherein the high-voltage
cathode is selected from LiFePO4 (LFP), LiMn2 O4 (LMO),
LiCoO 2 (LCO), LiNi 113 Mn 113 Co 113 O 2 (NMC), and
40
LiNi 0 _8 Co 0 _15 Al 0 _05 OiNCA).
11. The battery of claim 10, wherein the negative electrode is a graphitic anode.
12. A rechargeable battery comprising:
wherein R 1 and R9 are each CH 3 or CF 3 ,
a
negative electrode;
R3 and R7 are independently selected from the group 45
a
positive electrode;
consisting of H, alkyl, perfluoroalkyl, alkylaryl,
an electrolyte comprising a charge-carrying medium; and
alkoxyaryl, alkylcarboxyl, aryl carbonyl, haloalkyl,
a redox shuttle comprising the compound of claim 5.
perfluoroalkyl, glycols, haloaryl, a negative electro13. A battery comprising a passivating electrolyte addilyte, and a polymer; and
50 tive, wherein the passivating electrolyte additive comprises
R 10 is selected from the group consisting of aryl,
the compound of claim 5.
alkylaryl, alkoxyaryl, aryl carbonyl, perfluoroaryl,
14. The battery of claim 13, wherein the battery is selected
haloaryl, an oligomer, and a polymer;
from the group consisting of a lithium-ion battery, a lithiuma compound selected from the group consisting of:
air battery, and a sodium-ion battery.
55
15. A battery comprising a photopolymerization initiator
or photoredox catalyst, wherein the photopolymerization
initiator or photoredox catalyst comprises the compound of
claim 5.
16. A battery comprising an electrode material, wherein
CH;
CH;
60
the electrode material comprises the compound of claim 5.
17. The battery of claim 16, wherein the battery is a
non-aqueous redox flow battery.
and
18. An array comprising two or more of the battery of
s
#
65 claim 6.
19. The array of claim 18, wherein the two or more battery
are connected in a series.

Q

NX)
CC
I

,

US 10,854,911 B2
27

28

20. A rechargeable battery comprising:

a negative electrode;
a positive electrode; and
an electrolyte comprising the compound of claim 1.
21. A rechargeable battery comprising:
a negative electrode;
a positive electrode;
an electrolyte comprising a charge-carrying medium; and
a redox shuttle comprising the compound of claim 1.

* * * * *
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